A Novel Semi-biosynthetic Route for Artemisinin Production Using Engineered Substrate-Promiscuous P450 <sub>BM3</sub> — Jeffrey A. Dietrich (2009) | RDL Network
A Novel Semi-biosynthetic Route for Artemisinin Production Using Engineered Substrate-Promiscuous P450 <sub>BM3</sub>
Article 2009 en
Authors
JD
Jeffrey A. Dietrich
YY
Yasuo Yoshikuni
KF
Karl J. Fisher
Abstract
1 min read
Production of fine chemicals from heterologous pathways in microbial hosts is frequently hindered by insufficient knowledge of the native metabolic pathway and its cognate enzymes; often the pathway is unresolved, and the enzymes lack detailed characterization. An alternative paradigm to using native pathways is de novo pathway design using well-characterized, substrate-promiscuous enzymes. We demonstrate this concept using P450(BM3) from Bacillus megaterium. Using a computer model, we illustrate how key P450(BM3) active site mutations enable binding of the non-native substrate amorphadiene. Incorporating these mutations into P450(BM3) enabled the selective oxidation of amorphadiene artemisinic-11S,12-epoxide, at titers of 250 mg L(-1) in E. coli. We also demonstrate high-yielding, selective transformations to dihydroartemisinic acid, the immediate precursor to the high-value antimalarial drug artemisinin.
Justin B. Siegel, Amanda Lee Smith, Sean Poust, Adam J. Wargacki, Arren Bar‐Even, Catherine Louw, Betty Shen, Christopher B. Eiben, Huu M. Tran, Εlad Noor, Jasmine L. Gallaher, Jacob B. Bale, Yasuo Yoshikuni, Michael H. Gelb, Jay D Keasling, Barry Stoddard, Mary E. Lidstrom, David Baker
Discussion(0)
No comments yet. Be the first to comment.